Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Prediabetes in Acute MI
NCT03658031Phase 3Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prediabetes and myocardial infarction (MI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Incidence rate of Type 2 Diabetes Mellitus (Progression from Prediabetes) at 36 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
prediabetesmyocardial infarction (MI)
Beyond the preview
Go deeper on NCT03658031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658031.